Artemis Investment Management LLP Sells 69,340 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Artemis Investment Management LLP lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 473,564 shares of the company’s stock after selling 69,340 shares during the quarter. Artemis Investment Management LLP’s holdings in Teva Pharmaceutical Industries were worth $10,437,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of TEVA. Hennessy Advisors Inc. lifted its holdings in Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Hennessy Advisors Inc. now owns 726,600 shares of the company’s stock worth $16,014,000 after buying an additional 46,300 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 19.8% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 371,583 shares of the company’s stock worth $8,190,000 after purchasing an additional 61,467 shares in the last quarter. Contravisory Investment Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $221,000. Redhawk Wealth Advisors Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $1,155,000. Finally, Park Avenue Securities LLC increased its stake in Teva Pharmaceutical Industries by 23.2% in the 4th quarter. Park Avenue Securities LLC now owns 12,434 shares of the company’s stock worth $274,000 after acquiring an additional 2,341 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $22.13.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $21.97 on Monday. The stock has a market cap of $24.89 billion, a PE ratio of -25.84, a P/E/G ratio of 1.06 and a beta of 0.73. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock has a 50 day moving average price of $19.24 and a 200 day moving average price of $18.22. Teva Pharmaceutical Industries Limited has a one year low of $10.86 and a one year high of $22.80.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.